502486-89-7 Usage
Uses
Used in Pharmaceutical Industry:
NIDA-41020 is used as a therapeutic agent for the treatment of addiction and substance abuse. It targets the CB1 cannabinoid receptors, which are involved in the rewarding and reinforcing effects of drugs like opiates and nicotine. By blocking these receptors, NIDA-41020 can potentially reduce cravings and withdrawal symptoms, aiding in the recovery process for individuals struggling with addiction.
Used in Research and Development:
NIDA-41020 is also used as a research tool to study the role of CB1 cannabinoid receptors in various physiological and pathological processes. This can help scientists better understand the mechanisms underlying addiction and develop new therapeutic strategies for the treatment of substance abuse disorders.
Biochem/physiol Actions
NIDA-41020 is a CB1 cannabinoid receptor antagonist. NIDA-41020 is structurally similar to Rimonabant, which is currently in clinical development. NIDA-41020 is less lipophilic; developed at NIDA as a potential radioligand for CB1 receptors, Ki = 4.1 nM [in comparison AM 251, AM 281, SR 141716 (Rimonabant) have Ki of 0.6, 4.5 and 1.8 nM respectively].
Check Digit Verification of cas no
The CAS Registry Mumber 502486-89-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,2,4,8 and 6 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 502486-89:
(8*5)+(7*0)+(6*2)+(5*4)+(4*8)+(3*6)+(2*8)+(1*9)=147
147 % 10 = 7
So 502486-89-7 is a valid CAS Registry Number.
502486-89-7Relevant academic research and scientific papers
Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: Development of central cannabinoid receptor ligands with lower lipophilicity
Katoch-Rouse, Reeti,Pavlova, Olga A.,Caulder, Tara,Hoffman, Alexander F.,Mukhin, Alexey G.,Horti, Andrew G.
, p. 642 - 645 (2007/10/03)
Exploration of the central CB1 cannabinoid receptors using positron emission tomography (PET) will allow for an understanding of the pharmacological and physiological role played by these receptors in the CNS. Current tracers are highly lipophi
